Search Results
Aug 12, 2026, 16:05 ET Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
product candidate, toward a Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Collectively, these milestones support the planned pivotal Phase 3 superiority study, expected
More news about: Armata Pharmaceuticals, Inc.
Jul 20, 2026, 07:00 ET Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
candidate, toward a planned Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA").
More news about: Armata Pharmaceuticals, Inc.
Jul 13, 2026, 07:00 ET Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received
More news about: Armata Pharmaceuticals, Inc.
Jun 23, 2026, 07:00 ET Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
adjunct treatment of complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). The additional $2.5 million is intended to fund key activities to support Phase 3 readiness of
More news about: Armata Pharmaceuticals, Inc.
Jun 09, 2026, 10:14 ET Onkos Surgical® Receives FDA 510(k) Clearance for Application of NanoCept® Antibacterial Technology to Titanium Implants in the ELEOS™ Limb Salvage System
extensive preclinical testing, demonstrating a reduction in bacteria commonly found in the operating room, including Staphylococcus aureus (MRSA and MSSA), Cutibacterium acnes, Escherichia coli, and Pseudomonas aeruginosa."Expanding NanoCept onto titanium implants represents
More news about: ONKOS SURGICAL
Jun 08, 2026, 10:01 ET Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
alpha-toxin produced by Staphylococcus aureus, a major virulence factor present in both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By inhibiting this toxin, AR-301 helps limit toxin-induced damage to host tissues while maintaining immune cell functionality. Since its mechanism
More news about: DelveInsight Business Research, LLP
May 28, 2026, 09:05 ET CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant."Launching
More news about: Cumberland Pharmaceuticals Inc.
May 13, 2026, 16:30 ET Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
intravenously administered multi-phage therapeutic, into a Phase 3 superiority study in complicated SAB caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").The study is expected to initiate in the second half of 2026.
More news about: Armata Pharmaceuticals, Inc.
May 07, 2026, 07:00 ET Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").
More news about: Armata Pharmaceuticals, Inc.
Mar 19, 2026, 07:00 ET Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Disease Product ("QIDP") for adjunct treatment of complicated S. aureus bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").To achieve QIDP designation, a drug candidate must be intended to treat serious
More news about: Armata Pharmaceuticals, Inc.
Feb 23, 2026, 07:00 ET Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").
More news about: Armata Pharmaceuticals, Inc.
Jan 13, 2026, 07:42 ET Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
phage cocktail, for the treatment of complicated bacteremia caused by Staphylococcus aureus, including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains.The diSArm study (
More news about: Armata Pharmaceuticals, Inc.
Nov 18, 2025, 07:00 ET Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
was well-tolerated with clinical efficacy against both methicillin-resistant S. aureus ("MRSA") and methicillin-sensitive S. aureus ("MSSA"), and patients treated with AP-SA02 showed trends toward rapid normalization of key predictors of mortality and complications in SAB including C-reactive
More news about: Armata Pharmaceuticals, Inc.
Oct 22, 2025, 11:10 ET Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
group. AP-SA02 appears safe with clinical efficacy against both MRSA and methicillin-sensitive S. aureus ("MSSA") and trends toward earlier resolution and shorter hospitalization, with no evidence of relapse four weeks post-therapy.
More news about: Armata Pharmaceuticals, Inc.
Oct 14, 2025, 07:00 ET Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
the treatment of complicated bacteremia caused by Staphylococcus aureus (S. aureus), including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains. The diSArm study (
More news about: Armata Pharmaceuticals, Inc.
Oct 13, 2025, 09:05 ET CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA. Vibativ is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours and penetration
More news about: Cumberland Pharmaceuticals Inc.
Sep 29, 2025, 09:05 ET TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
More news about: Cumberland Pharmaceuticals Inc.